Table 6.
Amyloid-related imaging abnormality findings by APOE ε4 genotype and severity of amyloid-related imaging abnormalities-vasogenic edema events
| Placebo (n = 266) |
Gantenerumab 105 mg (n = 271) |
Gantenerumab 225 mg (n = 260) |
|
|---|---|---|---|
| ARIA-E | 2 (0.8%) | 18 (6.6%) | 35 (13.5%)a |
| 0ε4 patients | 2 (2.5%) | 1 (1.8%) | 11 (11.0%) |
| 1ε4 patients | 0 | 6 (5.4%) | 24 (15.0%) |
| 2ε4 patients | 0 | 11 (10.7%) | – |
| Maximum severity of ARIA–E, mean (±SD)b | 4.0 (4.2) | 4.0 (2.1) | 5.7 (6.9) |
| ARIA-H | 35 (13.2%) | 62 (22.9%) | 42 (16.2%)a |
| 0ε4 patients | 4 (5.1%) | 7 (12.3%) | 11 (11.0%) |
| 1ε4 patients | 19 (14.2%) | 22 (19.8%) | 31 (19.4%) |
| 2ε4 patients | 12 (22.6%) | 33 (32.0%) | – |
ARIA-E Amyloid-related imaging abnormalities-vasogenic edema, ARIA-H Amyloid-related imaging abnormalities-hemosiderin
aBy design, there were no APOE 2ε4 patients in the gantenerumab 225 mg arm
bARIA-E rating scale 28